FDA approves oral treatment for opioid-induced constipation

The FDA has approved the oral treatment for opioid-induced constipation naloxegol (Movantik), according to a Gastroenterology & Endoscopy News report.

Advertisement

Movantik is designed for adults with chronic non-cancer pain. The drug is a peripherally acting mu-opiod-receptor antagonist used to decrease the constipation side effect of opioids, according to the report.

More articles on gastroenterology:
19 things to know about GI compensation & satisfaction in 2014
AGA releases new tool for Crohn’s disease treatment
How has the Obama presidency affected the field of GI?

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.